Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Golimumab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Dr. Reddy\'s Laboratories
Deal Size : Undisclosed
Deal Type : Agreement
Bio-Thera, Dr. Reddy's Sign Agreement for Stelara, Simponi Biosimilars in SE Asia
Details : Under the agreement, Bio-Thera will maintain responsibility for the development of BAT2506 (Golimumab), while Reddy will have exclusive rights to commercialize the product in the Southeast Asia.
Product Name : BAT2506
Product Type : Antibody
Upfront Cash : Undisclosed
March 27, 2025
Lead Product(s) : Golimumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Dr. Reddy\'s Laboratories
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Golimumab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Accord BioPharma
Deal Size : $164.5 million
Deal Type : Licensing Agreement
Accord BioPharma Licenses BAT2506, A Golimumab Biosimilar, from Bio-Thera
Details : Under the licensing agreement, Bio-Thera will maintain responsibility for the development of BAT2506 (gollmumab), while Accord will have exclusive rights to commercialize the product in the US.
Product Name : BAT2506
Product Type : Antibody
Upfront Cash : $21.0 million
February 10, 2025
Lead Product(s) : Golimumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Accord BioPharma
Deal Size : $164.5 million
Deal Type : Licensing Agreement
Lead Product(s) : Golimumab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bio-Thera's BAT2506 Biosimilar to Simponi® Gains EU Regulatory Filing Acceptance
Details : BAT2506 (golimumab) is a biosimilar candidate to Simponi, which acts as TNF alpha inhibitor. It is being evaluated for treating moderately to severe rheumatoid arthritis & psoriatic aithritis.
Product Name : BAT2506
Product Type : Antibody
Upfront Cash : Inapplicable
February 07, 2025
Lead Product(s) : Golimumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Golimumab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Teva Pharmaceutical Industries
Deal Size : Inapplicable
Deal Type : Inapplicable
Alvotech and Teva Announce Filing Acceptance for AVT05, Biosimilar to Simponi®
Details : AVT05 is a biosimilar candidate for Simponi and Simponi Aria (golimumab). Golimumab is a monoclonal antibody that inhibits TNF alpha implicated in several chronic inflammatory diseases.
Product Name : AVT05
Product Type : Antibody
Upfront Cash : Inapplicable
January 27, 2025
Lead Product(s) : Golimumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Teva Pharmaceutical Industries
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Golimumab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Financing
Alvotech Announces Closing of Private Debt Financing
Details : The net proceeds for this financing will be used to fund the clinical advancement of company's late-stage product AVT05 (golimumab), which is being evaluated for the treatment of rheumatoid arthritis.
Product Name : AVT05
Product Type : Antibody
Upfront Cash : Undisclosed
November 07, 2024
Lead Product(s) : Golimumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Golimumab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : STADA Arzneimittel
Deal Size : $157.5 million
Deal Type : Licensing Agreement
Bio-Thera and STADA Reach Agreement for BAT2506 Biosimilar in the EU and UK
Details : Under the agreement, Bio-Thera Solutions will maintain responsibility for development, manufacturing, and supply of BAT2506, a biosimilar candidate to Simponi® (golimumab).
Product Name : BAT2506
Product Type : Antibody
Upfront Cash : $10.0 million
May 28, 2024
Lead Product(s) : Golimumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : STADA Arzneimittel
Deal Size : $157.5 million
Deal Type : Licensing Agreement
Lead Product(s) : Golimumab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alvotech Announces Results from Confirmatory Study for AVT05 Biosimilar to Simponi®
Details : AVT05 (golimumab) is a TNF blocker indicated for treating moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis in adults.
Product Name : AVT05
Product Type : Antibody
Upfront Cash : Inapplicable
April 24, 2024
Lead Product(s) : Golimumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Golimumab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
EMA Accepts MAA for AVT05, a Proposed Simponi® Biosimilar
Details : AVT05 is a biosimilar candidate for Simponi and Simponi Aria (golimumab). Golimumab is a monoclonal antibody that inhibits TNF alpha implicated in several chronic inflammatory diseases.
Product Name : AVT05
Product Type : Antibody
Upfront Cash : Inapplicable
April 11, 2024
Lead Product(s) : Golimumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Golimumab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AVT05 (golimumab) is a TNF alpha Inhibitor antibody drug therapy, administered intravenously, it is being investigated for rheumatoid arthritis management.
Product Name : AVT05
Product Type : Antibody
Upfront Cash : Inapplicable
November 29, 2023
Lead Product(s) : Golimumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Golimumab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AVT05 (golimumab) is a biosimilar candidate for Simponi® and Simponi Aria®. It is a monoclonal antibody that inhibitsTNF alpha, elevated TNF alpha levels have been implicated in several chronic inflammatory diseases such as rheumatoid arthritis, psoria...
Product Name : AVT05
Product Type : Antibody
Upfront Cash : Inapplicable
November 01, 2023
Lead Product(s) : Golimumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable